GHP Noetic Science-Psychedelic Pharma Past Earnings Performance
Past criteria checks 0/6
GHP Noetic Science-Psychedelic Pharma has been growing earnings at an average annual rate of 32.1%, while the Capital Markets industry saw earnings growing at 12.1% annually. Revenues have been growing at an average rate of 15.9% per year.
Key information
32.1%
Earnings growth rate
32.1%
EPS growth rate
Capital Markets Industry Growth | 12.1% |
Revenue growth rate | 15.9% |
Return on equity | -4.9% |
Net Margin | -609.9% |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How GHP Noetic Science-Psychedelic Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 0 | 0 | 0 | 0 |
30 Sep 22 | 0 | 0 | 0 | 0 |
30 Jun 22 | 0 | 0 | 0 | 0 |
31 Mar 22 | 0 | 0 | 0 | 0 |
31 Dec 21 | 0 | 0 | 0 | 0 |
30 Sep 21 | 0 | 0 | 0 | 0 |
31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: PSYF.P is currently unprofitable.
Growing Profit Margin: PSYF.P is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PSYF.P's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PSYF.P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PSYF.P is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (-7.1%).
Return on Equity
High ROE: PSYF.P has a negative Return on Equity (-4.91%), as it is currently unprofitable.